Coexpression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma

Cancer Biology and Therapy

Volumn 5, Issue 6, 2006, Pages 582-585

  Gong, Kan ^a   Zhang, Ning ^b   Zhang, Zheng ^a   Na, Yanqun ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Epo; EpoR; Pathogenesis; Sporadic renal cell carcinoma; VHL mutation

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; VASCULOTROPIN;

ARTICLE; CARCINOGENESIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VON HIPPEL LINDAU DISEASE; WESTERN BLOTTING;

EID: 33745802020     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.6.2709     Document Type: Article

References (27)

1. Singh AD, Shields CL, Shields JA. von Hippel-Lindau Disease. Survey of Ophthalmology 2001; 46:117-42.
2. Hes FJ, van der Luijt RB, Lips CJM. Clinical management of Von Hippel-Lindau (VHL) disease. The Netherlands Journal of Medicine 2001; 59:225-34.
3. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH. von Hippel-Lindau disease. The Lancet 2003; 361:2059-67.
4. SANO T and Horjguchi H. Von Hippel-Lindau Disease. Microscopy Research and Technique 2003; 60:159-64 .
5. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan DR, Dean A, Glavac D, Richards FM, Crossey P.A, Ferguson-Smith MA, Le Paslier D, Chumakov I, Cohen D, Chinault CA, Maher E.R, Linehan WM, Zbar B. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317-20.
6. Pufe T, Lemke A, Kurz B, Petersen W, Tillmann B, Grodzinsky AJ, Mentlein R. Mechanical Overload Induces VEGF in Cartilage Discs via Hypoxia-Inducible Factor. Am J Pathol 2004; 164: 185-92.
7. Hanze J, Eul BG, Savai R, Krick S, Goyal P, Grimminger F, Seeger W, Rose F. RNA interference for HIF-1alpha inhibits its downstream signalling and affects cellular proliferation. Biochem Biophys Res Commun 2003; 312:571-7.
8. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI, Tumor and Angiogenesis Research Group. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 2002; 95:1055-63.
9. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1:237-46.
10. William G, Kaelin JR. The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing. J Am Soc Nephrol 2003; 14: 2703-11.
11. Vortmeyer AO, Yuan Q, Lee YS, Zhuang Z, Oldfield EH. Developmental effects of von Hippel-Lindau gene deficiency. Ann Neurol 2004; 55:721-8.
12. Vortmeyer AO, Frank S, Jeong SY, Yuan K, Ikejiri B, Lee YS, Bhowmick D, Lonser RR, Smith R, Rodgers G, Oldfield EH, Zhuang Z. Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res 2003; 63:7051-5.
13. Lee YS, Vortmeyer AO, Lubensky IA, Vogel TW, Ikejiri B, Ferlicot S, Benoit G, Giraud S, Oldfield EH, Linehan WM, Teh BT, Richard S, Zhuang Z. Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res 2005; 11:1059-64.
14. Vogel TW, Vortmeyer AO, Lubensky IA, Lee YS, Furuta M, Ikejiri B, Kim HJ, Lonser RR, Oldfield EH, Zhuang Z. Coexpression of erythropoietin and its receptor in endolymphatic sac tumors. J Neurosurg 2005; 103:284-8.
15. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2:673-82.
16. Maxwell PH, Pugh CW, Ratcliffe PJ. The pVHL-hIF-1 system. A key mediator of oxygen homeostasis. Adv Exp Med Biol 2001; 502:365-76.
17. Linehan WM, Walther MM and Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170:2163-72.
18. Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG. Understanding familial and non-familial renal cell carcinoma. Hum Mol Genet 2002; 11:2489-98.
19. Oya M and Murai M. Renal cell carcinoma: relevance of pathology. Curr Opin Urol 2003; 13:445-9.
20. Rathmell WK and Godley PA. Renal cell carcinoma. Current Opinion in Oncology 2004;16:247-52.
21. Takahashi M, Kahnosk RI, Gross D, Nicol D. The Familial adult renal neoplasia. J Med Genet 2002; 39:1-5.
22. Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T, Moriyama M, Kobayashi K, Sakai N, Kaneko S, Kawakami S, Baba M, Nakaigawa N, Nagashima Y, Nakatani Y, Hosaka M. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002; 34:58-68.
23. Gong K, Zhang ZHW, Xing DQ, Na X, Wu G, Na YQ. Frequent somatic mutations of the von Hippel-Lindau (VHL) tumor suppressor gene in Chinese primary sporadic human renal clear cell carcinomas. Natl Med J China 2001; 81:142-4.
24. Kertesz N, Wu J, Chen TH, Sucov HM, Wu H. The role of erythropoietin in regulating angiogenesis. Developmental Biology 2004; 276:101-10.
25. Westenfelder C and Baranowski RL. Erythropoietin stimulate proliferationg of human renal carcinoma cells. Kidney International 2000; 58:647-57.
26. Horster MF, Braun GS, Huber SM. Embryonic rental epithelia: induction, nephrogenesis, and cell differentiation. Physiol Rev 1999; 79:1157-91.
27. Mitjavila MT, Le Couedic JP, Casadevall N, Navarro S, Villeval JL, Dubart A, Vainchenker W. Autocrine stimulation by erythropoietin and autonomous growth of human erythroid leukemic cells in vitro. J Clin Invest 1991; 88:789-97.